ASSEMBLY BIOSCIENCES, INC.ASMBEarnings & Financial Report
Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.
ASMB Q3 FY2025 Key Financial Metrics
Revenue
$10.8M
Gross Profit
N/A
Operating Profit
$-10.9M
Net Profit
$-9.2M
Gross Margin
N/A
Operating Margin
-100.9%
Net Margin
-85.2%
YoY Growth
57.6%
EPS
$-0.72
ASSEMBLY BIOSCIENCES, INC. Q3 FY2025 Financial Summary
ASSEMBLY BIOSCIENCES, INC. reported revenue of $10.8M (up 57.6% YoY) for Q3 FY2025, with a net profit of $-9.2M (up 4.3% YoY) (-85.2% margin).
Key Financial Metrics
| Total Revenue | $10.8M |
|---|---|
| Net Profit | $-9.2M |
| Gross Margin | N/A |
| Operating Margin | -100.9% |
| Report Period | Q3 FY2025 |
ASSEMBLY BIOSCIENCES, INC. Annual Revenue by Year
ASSEMBLY BIOSCIENCES, INC. annual revenue history includes year-by-year totals (for example, 2024 revenue was $28.5M).
ASSEMBLY BIOSCIENCES, INC. Quarterly Revenue & Net Profit History
ASSEMBLY BIOSCIENCES, INC. results over the last 7 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $10.8M | +57.6% | $-9.2M | -85.2% |
| Q2 FY2025 | $9.6M | +12.8% | $-10.2M | -105.9% |
| Q1 FY2025 | $9.4M | +62.8% | $-8.8M | -93.6% |
| Q4 FY2024 | $7.4M | +2.7% | N/A | N/A |
| Q3 FY2024 | $6.8M | — | $-9.6M | -140.4% |
| Q2 FY2024 | $8.5M | — | $-11.2M | -130.7% |
| Q1 FY2024 | $5.8M | — | $-9.1M | -156.9% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $5.8M | $8.5M | $6.8M | $7.4M | $9.4M | $9.6M | $10.8M |
| YoY Growth | N/A | N/A | N/A | 2.7% | 62.8% | 12.8% | 57.6% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|
| Assets | $119.9M | $115.3M | $100.3M | $119.2M | $99.0M | $80.8M | $240.0M |
| Liabilities | $87.3M | $80.6M | $74.3M | $85.8M | $71.9M | $62.7M | $57.3M |
| Equity | $32.6M | $34.7M | $26.0M | $33.4M | $27.1M | $18.1M | $182.7M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-18.4M | $-17.1M | $-15.2M | $-51.1M | $-23.4M | $-16.8M | $-15.1M |